INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 149 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2018. The put-call ratio across all filers is 0.95 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $7,441,000 | -33.9% | 118,188 | +30.2% | 1.28% | -1.2% |
| Q4 2019 | $11,252,000 | +5.1% | 90,804 | -43.7% | 1.29% | +40.5% |
| Q3 2019 | $10,711,000 | -48.8% | 161,406 | -22.3% | 0.92% | -47.0% |
| Q4 2018 | $20,930,000 | -29.3% | 207,657 | -11.3% | 1.74% | +8.8% |
| Q3 2018 | $29,585,000 | -8.8% | 234,135 | -39.4% | 1.60% | -10.5% |
| Q2 2018 | $32,423,000 | +51.2% | 386,397 | +10.9% | 1.78% | +42.5% |
| Q1 2018 | $21,437,000 | – | 348,454 | – | 1.25% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 234,375 | $23,623,000 | 22.67% |
| Boxer Capital, LLC | 600,000 | $60,474,000 | 7.47% |
| DLD Asset Management, LP | 834,600 | $84,136,000 | 5.77% |
| GREAT POINT PARTNERS LLC | 200,000 | $20,158,000 | 2.55% |
| BB BIOTECH AG | 575,719 | $58,027,000 | 1.86% |
| Elk Creek Partners, LLC | 207,657 | $20,930,000 | 1.74% |
| ALTRINSIC GLOBAL ADVISORS LLC | 277,944 | $28,014,000 | 1.34% |
| Sarissa Capital Management LP | 54,000 | $5,442,000 | 1.21% |
| QCM Cayman, Ltd. | 2,181 | $220,000 | 0.90% |
| Opus Point Partners Management, LLC | 3,534 | $356,000 | 0.78% |